Vivaldi Biosciences
Biotechnology, 3185-a Rampart Road, Fort Collins, Colorado, 80523, United States, 11-50 Employees
Phone Number: 97********
Who is VIVALDI BIOSCIENCES
Vivaldi Biosciences is developing vaccines for protection against epidemic and pandemic viral respiratory diseases using its Delta NS1 vector and innovative cell-based production technolo...
Read More
-
Headquarters: 3185-a Rampart Road, Fort Collins, Colorado, 80523, United States
-
Date Founded: 2006
-
Employees: 11-50
-
Revenue: $250 Million to $500 Million
-
Active Tech Stack: See technologies
-
CEO:
Bill Wick
Email
Phone
Industry: Biotechnology
SIC Code: 5912
|
NAICS Code: 424210 |
Show More
Does something look wrong? Fix it. | View contact records from VIVALDI BIOSCIENCES
Vivaldi Biosciences Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Vivaldi Biosciences
Answer: Vivaldi Biosciences's headquarters are located at 3185-a Rampart Road, Fort Collins, Colorado, 80523, United States
Answer: Vivaldi Biosciences's phone number is 97********
Answer: Vivaldi Biosciences's official website is https://vivaldibiosciences.com
Answer: Vivaldi Biosciences's revenue is $250 Million to $500 Million
Answer: Vivaldi Biosciences's SIC: 5912
Answer: Vivaldi Biosciences's NAICS: 424210
Answer: Vivaldi Biosciences has 11-50 employees
Answer: Vivaldi Biosciences is in Biotechnology
Answer: Vivaldi Biosciences contact info: Phone number: 97******** Website: https://vivaldibiosciences.com
Answer: Vivaldi Biosciences is developing vaccines for protection against epidemic and pandemic viral respiratory diseases using its Delta NS1 vector and innovative cell-based production technologies. Vivaldis DeltaFLU universal influenza vaccine is in Phase 2 clinical development. Its Delta-19 universal influenza/Covid-19 vaccine will enter clinical trials in 2021. Delta NS1 is a versatile and robust technology platform for self-adjuvanting vaccines administered by nasal spray. Delta NS1 is a replication-deficient vaccine vector based on a genetically modified, safely attenuated influenza virus strain. Delta NS1-based vaccines have the unique ability to rapidly induce interferon, generating protection against circulating viruses entering the nasal passages, and activating systemic antibody and cell-based protective immunity.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month